Want to see TSE:OTC full AI Analyst Report?
OTC Stock Chart & Stats
C$0.43
-C$0.05(-9.62%)
At close: 4:00 PM EDT
C$0.43
-C$0.05(-9.62%)
Day’s Range― - ―
52-Week RangeC$0.35 - C$1.40
Previous CloseN/A
Volume8.89K
Average Volume (3M)23.89K
Market Cap
C$63.35M
Enterprise ValueC$63.76
Total Cash (Recent Filing)C$88.74K
Total Debt (Recent Filing)C$4.31M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding143,983,700
10 Day Avg. Volume24,274
30 Day Avg. Volume23,892
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)-18.65
Price to Sales (P/S)0.00
P/FCF Ratio-21.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Ophthalmic Product DevelopmentA focused ophthalmology program gives the company a defined development and commercialization pathway rather than a broad, unfocused portfolio. The Bionic Lens is designed as a potential alternative to traditional corrective eyewear or conventional cataract lenses, creating a clear product objective.
Lower Debt Versus Prior YearThe reduction in total debt from 2025 to the latest trailing period provides a limited improvement in the capital structure and may reduce debt pressure if sustained. This does not offset negative equity or high leverage, but it is a constructive directional change in balance-sheet management.
Cash Losses Broadly Match Reported LossesFree cash flow being broadly in line with net losses indicates that reported losses are largely reflected in actual cash use rather than being driven mainly by large non-cash charges. This improves transparency around the economics of the current development stage, despite the continuing burn.
Bears Say
No Meaningful CommercializationPersistent zero revenue shows that the company has not yet achieved meaningful commercialization of its ophthalmic technology. Until revenue begins, operating performance depends on development progress and external financing, making the business model more vulnerable to delays in regulatory or market adoption milestones.
Widening Losses And Unfavorable Cost StructureLosses are widening while revenue remains absent and gross profit stays negative, indicating that expenses are increasing without an offsetting commercial base. Continued deterioration reduces the company’s ability to fund development internally and raises the financial hurdle for reaching sustainable profitability.
Negative Equity And Elevated LeverageNegative shareholders’ equity and debt that is large relative to total assets signal substantial capitalization risk. This weak balance sheet limits financial flexibility, increases reliance on external funding, and could make future financing more dilutive or difficult if operating losses persist.
Ocumetics Technology Corp News
OTC FAQ
What was Ocumetics Technology Corp’s price range in the past 12 months?
Ocumetics Technology Corp lowest stock price was C$0.35 and its highest was C$1.40 in the past 12 months.
What is Ocumetics Technology Corp’s market cap?
Ocumetics Technology Corp’s market cap is C$63.35M.
When is Ocumetics Technology Corp’s upcoming earnings report date?
Ocumetics Technology Corp’s upcoming earnings report date is Dec 01, 2026 which is in 66 days.
How were Ocumetics Technology Corp’s earnings last quarter?
Ocumetics Technology Corp released its earnings results on Aug 28, 2026. The company reported -C$0.004 earnings per share for the quarter.
Is Ocumetics Technology Corp overvalued?
According to Wall Street analysts Ocumetics Technology Corp’s price is currently Overvalued.
Does Ocumetics Technology Corp pay dividends?
Ocumetics Technology Corp does not currently pay dividends.
What is Ocumetics Technology Corp’s EPS estimate?
Ocumetics Technology Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ocumetics Technology Corp have?
Ocumetics Technology Corp has 143,983,700 shares outstanding.
What happened to Ocumetics Technology Corp’s price movement after its last earnings report?
Ocumetics Technology Corp reported an EPS of -C$0.004 in its last earnings report. Following the earnings report the stock price went up 1.149%.
Which hedge fund is a major shareholder of Ocumetics Technology Corp?
Currently, no hedge funds are holding shares in TSE:OTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ocumetics Technology Corp
Ocumetics Technology Corp. is an innovation-driven enterprise specializing in the development and production of diverse optical lenses. One of its key innovations is the Bionic Lens, an expandable intraocular lens crafted to be implanted within the eye's natural lens compartment, offering a solution that eliminates the need for external vision correction. The company maintains its corporate headquarters in Calgary, Canada.
Technical Analysis
Aurora Spine
―
Covalon Technologies
―
Perimeter Medical Imaging AI
―
VentriPoint Diagnostics
―
Conavi Medical
―